LGD 4033 Review (Ligandrol)

You might have come across SARM (Selective Androgen Receptor Modulator), while searching for steroid alternatives. Well, in this article we will talk about one of the most popular SARM – LGD 4033.

LGD 4033 – What is it?

LGD 4033 is an oral SARM. It is also known as Ligandrol, VK5211, and Anabolicum. It was discovered by Ligand Pharmaceuticals and currently being researched and developed by Viking Therapeutics.

Ligandrol has been under constant research and has been recognized as a potential cure for various medical conditions including osteoporosis and cancer. It is very well accepted for its effects on building lean muscle mass and for its ability to both bulk and cut. It is one of the most potent performance enhancers and hence, they are in demand among the athletes, powerlifters and bodybuilders.

How does Ligandrol work?

Ligandrol targets the androgen receptors present in muscles and bones. LGD 4033 binds to these receptors and activates them. Thus, maintaining skeletal integrity and lean muscle mass in males. Unlike steroids, it does not enter the bloodstream and affect the other organs.

Two main features of this compound are – its anabolic activity and its disability to aromatize.

Visit: Anvarol Review

Due to its anabolic activity, there is an increase in muscle growth and repair. This is the reason it is also called as Anabolicum.

As it does not aromatize, i.e. it does not get converted into estrogen, there is no water retention in your body and does not trigger unwanted side effects like high blood pressure.

Anvarol Review BA

Benefits of LGD 4033

  • It helps in enhancing lean muscle mass due to its anabolic, muscle-building effects.
  • It increases your strength that would help you to train heavily and thereby, augmenting your muscle growth.
  • It speeds up the recovery of muscles and bones. As Ligandrol activates the androgen receptors in bones, it increases bone mineral density and therefore, helps in the formation of new bones in response to an injury.
  • It maintains muscle mass and also helps in burning extra body fat effectively. Hence, it can be used by bodybuilders for both bulking and cutting phases.
  • It does not have any unwanted side effects like steroids and causes no risk to other organs in the body.
  • It also improves cognitive health, which has a positive impact on bodybuilders by motivating and helping them to focus on their training.


Ligandrol is the best and the most potent SARM available and therefore, even small dosages of this compound are very effective. Researches have shown that dosages as low as 1mg can have significant progress in its results.

Hence, a dosage of 5-10 mg is recommended for appropriate results with minimal or no side effects.

It is recommended to continue with this dosage for 6-10 weeks. After a 4-5-week break, you can again start with the recommended doses of LGD 4033. After one cycle of LGD 4033, a Post Cycle Therapy of 4-5-week is recommended during which a SERM or an anti-estrogen can be consumed for protecting you against any possible side effects of Ligandrol.

Ligandrol can also be stacked with other SARM supplements, in both bulking and cutting phases, to increase its efficiency.

Side effects of Ligandrol

As LGD 4033 is very selective in its actions, it does not have any harsh or dangerous side effects if used correctly as per recommendations. However, they do cause a few common side effects like nausea, headache, and low libido. The consumption of Ligandrol affects the levels of testosterone in your body which causes these minor side effects. This is the reason, a Post Cycle Therapy with quality ingredients is required to overcome these side effects.

However, Ligandrol is an investigational drug as the long-term effects of LGD 4033 are not yet known. Therefore, it is neither approved by the Food and Drug Administration of America (FDA) nor by the World Anti-doping Agency (WADA). Hence, you cannot use these if you are involved in a professional sport or tournament.

Leave a Reply

Your email address will not be published. Required fields are marked *